Elvia Cowan
Known title: SVP, Finance & CAOCIK: 0001960048
Associated companies
Transaction History
| PCVX | ▲ Buy | Option Exercise | 19,000 | $492K | 10/5/2026 | View on chart |
| PCVX | ▼ Sell | Open Market | 19,000 | $1.6M | 10/5/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 1,327 | $80K | 9/8/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 326 | $20K | 9/2/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 243 | $15K | 8/31/2026 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 3,000 | $78K | 4/7/2026 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,000 | $180K | 4/7/2026 | View on chart |
| PCVX | ▼ Sell | Open Market | 1,487 | $82K | 3/17/2026 | View on chart |
| PCVX | ▼ Sell | Open Market | 405 | $23K | 3/17/2026 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 2,500 | $65K | 3/11/2026 | View on chart |
| PCVX | ▼ Sell | Open Market | 2,500 | $146K | 3/11/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 495 | $29K | 3/9/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 326 | $20K | 3/2/2026 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 243 | $15K | 2/28/2026 | View on chart |
| PCVX | ▲ Buy | Grant | 10,681 | $0 | 2/26/2026 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 7,716 | $200K | 2/26/2026 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,907 | $235K | 12/23/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 6,716 | $322K | 12/23/2025 | View on chart |
| PCVX | ▼ Sell | Gift | 1,000 | $0 | 12/23/2025 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 482 | $16K | 9/8/2025 | View on chart |
| PCVX | ▲ Buy | Grant | 2,810 | $0 | 9/7/2025 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 242 | $8K | 9/2/2025 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 325 | $10K | 9/2/2025 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 325 | $23K | 3/3/2025 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 242 | $18K | 2/28/2025 | View on chart |
| PCVX | ▲ Buy | Grant | 5,379 | $0 | 2/27/2025 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 7,716 | $200K | 12/16/2024 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 5,000 | $130K | 9/3/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 5,000 | $538K | 9/3/2024 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 1,145 | $126K | 9/3/2024 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 5,000 | $130K | 7/16/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 5,000 | $425K | 7/16/2024 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 5,000 | $130K | 7/8/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 5,000 | $400K | 7/8/2024 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 324 | $23K | 3/2/2024 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 11,000 | $285K | 3/1/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 2,322 | $170K | 3/1/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,455 | $328K | 3/1/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,901 | $367K | 3/1/2024 | View on chart |
| PCVX | ▲ Buy | Grant | 5,400 | $0 | 2/29/2024 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 627 | $32K | 9/5/2023 | View on chart |
| PCVX | ▲ Buy | Grant | 7,250 | $0 | 3/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.